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Super-refractory status epilepticus (SRSE) is defined as status epilepticus that continues
24 h or more after the onset of anesthesia, and includes those cases in which epilepsy is
recurrent upon treatment reduction. We describe the presentation and successful man-
agement of a male patient with SRSE using the inhaled anesthetic isoflurane, and mild
hypothermia (HT).The potential utility of combined HT and volatile anesthesia is discussed.
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INTRODUCTION
A 32-year-old Kazakh male presented with status epilepti-
cus (tonic–clonic seizures) in Almaty, Kazakhstan, where he is
employed in a physically active profession. The only noted event
before the first seizure was a fever 7 days prior, which subsided
without medication. Emergency personnel terminated the initial
seizures with intravenous diazepam. Patient refused transport to
the hospital but developed a second episode of tonic–clonic seizure
several hours later. He was then treated at the hospital’s inten-
sive care unit (ICU) with benzodiazepines and antiepileptic drugs
(AEDs), which were unsuccessful. After 7 days of attempted man-
agement, the patient was transported by sanitary aviation to the
National Medical Holding in Astana, Kazakhstan for treatment by
our team.
Upon presentation in Astana, serum glucose and routine serum
electrolyte levels were within normal limits. Analyses revealed
the following values: hemoglobin, 10.5 g/dL; leukocyte count,
14× 109 cells/L with neutrophilia; lactate dehydrogenase, 459 U/L;
arterial blood gas, pH 7.3, PaCO2, 47 mmHg; PaO2, 75 mmHg;
HCO3, 22 mmol/L; and SaO2, 87%. Hemoglobin and serum elec-
trolytes indicate normal pulmonary and renal function, while
the high LDH may have indicated liver damage, such as what
is expected following the recent treatment with benzodiazepines.
Both ANA and ENA panels were negative, thereby not supporting
an autoimmune dysfunction. CSF was sterile and blood was nega-
tive for viruses. ECG showed normal left ventricular function and
no regional wall abnormalities.
Head CT initially showed no malformation upon ICU admis-
sion in Almaty; however, after 2 days of treatment in Astana,
CT showed cerebral edema (compression of third ventricle
and flattening of gyri). Edema and ICP were managed with
mannitol, and fever with chlortenoxicam. Tumors were not
evident from any scan. After 1 week of isoflurane and hypother-
mia (HT) treatment, head CT indicated a full return to normal
morphology.
PROTOCOLS
STANDARD PROTOCOL
Our ICU uses a standard protocol for evaluation and treatment of
status epilepticus. This protocol is as follows:
• management of airway by intubation and mechanical ven-
tilation, which is adjusted to maintain a pulse oximetry of
≥95% and/or PaO2 ≥80 mmHg and eucapnia (PCO2 of
35–40 mmHg);
• maintaining euvolemia using isotonic fluid to keep central
venous pressure equal 8–10 mmHg;
• inotropes to maintain mean arterial pressure above 80 mmHg;
• mild hypothermia (34–35°C);
• maintaining normoglycemia (4–8 mmol/L);
• standard seizure drugs (diazepam, phenytoin, sodium thiopen-
tal, propofol);
• antipyretic therapy (paracetamol, ketorolac);
• infusion therapy (normal saline, ringer’s lactate);
• continuous EEG monitoring;
• brain MRI and CT;
• comprehensive toxicology panel including drugs that frequently
cause seizures (i.e., isoniazid, tricyclic antidepressants, theo-
phylline, cocaine, sympathomimetics, alcohol, organophos-
phates, and cyclosporine);
• other laboratory tests: liver function tests, serial troponins, type
and hold, coagulation studies, arterial blood gas, AED lev-
els, toxicology screen (urine and blood), and inborn errors of
metabolism;
• lumbar puncture if not contraindicated.
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HYPOTHERMIA PROTOCOL
Hypothermia is induced and maintained using Blanketrol with
Maxi-Therm® (Cincinnati Sub-Zero): 34–35°C was achieved
within 5 h. Skin, esophageal, and axilla temperatures were mon-
itored hourly during intervention. Rewarming was performed
manually over 24 h (~0.12°C/h).
Hypothermia safety monitoring protocol:
• Metabolic status: serum electrolytes were monitored as per
clinical routine.
• Respiratory status: blood gases are monitored as per clinical
routine.
• Cardiovascular: heart rate, blood pressure, and use of inotropic
agents were recorded at baseline and every 4 h, for 96 h.
• Renal status: urine output and body weight were recorded daily
during the intervention interval. Serum BUN and creatinine
were monitored as per clinical routine.
• Hematological: PT/PTT will be acquired only if bleeding is sus-
pected based upon clinical symptoms or an unexplained fall in
hematocrit by more than 10%.
• Complete blood counts are monitored as per clinical routine.
• Infectious disease: results of blood cultures are recorded.
DVT prophylaxis
• If no contraindication, heparin 5000 U subcutaneous, 8 h.
Stress ulcer prophylaxis
• Famotidine 40 mg IVSS×1.
VAP prophylaxis
• Head of bed to 30°.
• Place in-line closed suction and perform aggressive pulmonary
evacuation.
Sedation/analgesia/anti-convulsants
• The use of sedative, hypnotic, and analgesic agents and anti-
convulsants is at the discretion of the intensivist.
TREATMENT AND OUTCOME
Figure 1 shows a schematic of the treatment/response timeline.
Initial therapy consisted of diazepam 0.15 mg/kg (10 mg bolus;
this dose was repeated after 5 min) and propofol 0.027 mg/kg/min,
valproic acid 2 g/day, and carbamazepine 200 mg twice daily. This
therapy was not sufficient to reduce seizures after 4 h and the
dose of propofol was increased to 0.09 mg/kg/min. To reduce
the continued hepatic damage (indicated by treatment and LDH
levels), propofol is a good first choice (1); however, it failed to
alleviate epileptic activity. As the combination of these drugs
continued to fail at 22 h, propofol was exchanged for sodium
thiopental (0.04 mg/kg/min) and 16 h later was increased to
0.07 mg/kg/min. Despite this therapy seizures continued (mon-
itored by continuous EEG recording), resulting in hemodynamic
instability with profound hypotension demanding vasopressors
(epinephrine, 0.1µg/kg/min and phenylephrine, 0.09µg/kg/min)
with continuous normal saline infusion.
After the first 48 h of attempted treatment, we then ini-
tiated general anesthesia with isoflurane [minimal alveolar
concentration (MAC) 1.0] and HT (34–35°C). Isoflurane was
associated with ameliorated epileptic discharges with adequate,
sustained EEG burst suppression within minutes of initiating.
Isoflurane was partly chosen because of its lesser association with
drug-induced hepatitis (2). Isoflurane MAC was then decreased to
0.7 and was not associated with worsened hemodynamic instabil-
ity. The administration of sodium thiopental and diazepam was
stopped and, 30 min after discontinuing these drugs, hemody-
namics started to stabilize. Epinephrine and phenylephrine were
decreased to 0.075 and 0.05µg/kg/min, respectively. Termina-
tion of seizures was determined by EEG and no seizure activity
was registered during the immediate 72 h after beginning isoflu-
rane administration. The patient was then rewarmed and isoflu-
rane inhalation was gradually stopped but, despite the continued
administration of valproic acid and carbamazepine, seizures reoc-
curred. Isoflurane anesthesia (MAC 0.7) was again initiated and
the patient was recooled to 34–35°C. This dosage was consid-
ered minimal to control seizures. Seizure control efficacy was
monitored by continuous EEG.
Two weeks later, isoflurane was gradually decreased to 0.2 MAC
over 24 h and finally stopped. The patient was rewarmed and con-
vulsions did not reoccur. Several unsuccessful attempts had been
made to remove the patient from HT and isoflurane over the 2-
week interval. Standard anticonvulsant therapy (valproic acid and
carbamazepine) was continued and 72 h later the patient was dis-
charged from the ICU to the step down unit and a week later from
the hospital.
In total, the patient was mechanically ventilated for 24 days
and this was complicated by ventilator-associated pneumonia. He
was successfully extubated and started on an intensive rehabili-
tation program with rapid improvement. After discharge to his
home, brain magnetic resonance imaging did not show any signs
of pathology 3 weeks after being extubated. A cognitive function
assessment was not performed by a psychologist at that time
since his mental and psychological functions were significantly
recovered. He returned back to work at 2 months after the event
with excellent and complete functional recovery and no known
neurological or psychological deficits.
BACKGROUND
Refractory status epilepticus (RSE) is continued seizures after the
failure of two or more AEDs. Common intravenous agents such
as diazepam, lorazepam, midazolam, and phenytoin used to treat
RSE have frequent problems with toxicity or efficacy (3–5). SRSE
is defined as status epilepticus that continues 24 h or more after
the onset of anesthesia, including those cases in which the status
epilepticus recurs on the reduction or withdrawal of anesthe-
sia. Status epilepticus is a neurological emergency that requires
immediate recognition and treatment and carries a significant
economic impact on the healthcare system (6). Annual incidence
in population-based studies ranges from 10 to 60 cases per 100,000
persons, annually (7, 8).
Super-refractory status epilepticus therapies and their out-
comes were recently and thoroughly summarized (9): 1168 SRSE
patients were described to have received 19 possible treatments
and all patients received some treatment combination. Midazolam
was used most frequently in 50% of all SRSE patients. Propofol
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FIGURE 1 | Clinical course and treatment timeline. Initial therapy included
diazepam (diaz) 0.15 mg/kg, and propofol (prop) 0.027 mg/kg/min. Four hours
later, the dose of propofol was increased to 0.09 mg/kg/min. Eighteen hours
later, prop was exchanged for sodium thiopental (TP). Twenty-six hours later,
general anesthesia was induced with isoflurane (isoflu) and HT initiated. After
seizures were dormant for 72 h, the patient was removed from isoflurane and
rewarmed, at which point, seizures returned. Isoflurane anesthesia and HT
were reinitiated and continued for 2 weeks, during which the patient was
stable without super-refractory status epilepticus (SRSE). Attempts to
withdraw from treatment were unsuccessful over these 2 weeks. The patient
was then gradually removed from isoflurane and HT, remained seizure-free for
72 h and was then released from the ICU.
and thiopental/phenobarbital were also common and used in 12
and 16% of cases, respectively. Overall, the expected outcomes for
SRSE are poor; only ~33% of patients recovered to baseline func-
tion. The authors note that the source of the SRSE inducing-injury
is likely a dominant determinant of ultimate outcome.
While no comprehensive trial has been performed with isoflu-
rane for SRSE treatment, anecdotal evidence and case studies sug-
gest that it is an efficacious alternative when standard drugs fail or
are contraindicated (such as with some concomitant chemother-
apy). There may, however, be limits to its utility as prolonged use in
two patients (34 and 87 days) was associated with subcortical white
matter hyperintensities on MRI, which was reversed upon discon-
tinuation (10). Short-term treatment appears to associate with
manageable risk, and in the small number of reported cases, isoflu-
rane was able to ablate seizures within minutes of anesthetization
(11). Ferlisi and Shorvon reviewed the data from 27 refractory
epileptic patients that were treated with inhalational anesthet-
ics (7 independent publications including those cited here) and
conclude that, indeed, this strategy initially controlled seizures in
100% of cases (9). However, there is an elevated risk for adverse
events, leading one to conclude that isoflurane’s utility is best
reserved until other treatments have failed (which is generally the
condition for SRSE).
The 2012 Guidelines for the evaluation and management of
status epilepticus (12) provides a brief assessment for alterna-
tive epilepsy treatment including both inhalational anesthetics and
HT. Hypothermia is attractive for several reasons: reduced edema,
fever prevention, strong acute efficacy for blocking seizures, and a
relatively low risk for adverse effect (13). Unfortunately, HT also
tends be a temporary solution, as epilepsy often reoccurs upon
warming. Investigations of HT for treating cardiac arrest indicate
that the method of inducing HT, the stability of body temperature
control, duration of HT and rate of rewarming all impact its effi-
cacy, and differences in the these variables between centers are
important to consider to understand inconsistencies between out-
comes following a neurological injury (14, 15). For example, in
one meta-analysis of traumatic brain injury, the authors included
studies that used many different techniques including different
methods for measuring core body temperature, different tem-
perature ranges over the HT maintenance phase, and different
rates of rewarming (16). Some degree of HT can be easily and
crudely implemented in clinical units and therefore there is an
enormous degree of variability between study techniques (17).
These questions need to be refined and answered to provide the
best treatments to SRSE.
DISCUSSION
In this case, standard therapy for status epilepticus was not effec-
tive; however, inhaled anesthesia with isoflurane paired with HT
showed excellent efficacy and was without significant adverse effect
(mild hypotension was managed with normal saline infusion and
low dose norepinephrine). Since SRSE incidence is too low to
readily perform a properly designed study, we intend for this case
study to serve as an illustration of the potentially beneficial role
of inhalation anesthesia with isoflurane and mild HT in SRSE
management.
Inhalational anesthesia with isoflurane and HT were effec-
tive in SRSE management, when even multiple anticonvulsive
drug therapies were ineffective. This treatment was also better
tolerated compared to high dose thiopental and other anticon-
vulsive medications. Persistent hypotension during the first days
was well corrected with normal saline infusion and low dose
vasopressors. Treatment with high dose diazepam and thiopen-
tal was not able to fully terminate convulsive activity, caused
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more profound hypotension and elevated hepatic enzymes (ALT,
AST). Electrolyte imbalances, kidney or liver damage, and dia-
betes were excluded according to normal arterial blood values.
During the first 24 h of isoflurane anesthesia, sodium thiopental
was gradually decreased and finally stopped. The patient was given
isoflurane anesthesia with MAC 0.7 and AEDs (carbamazepine,
phenytoin, phenobarbital at standard doses). During 20 days of
ICU treatment, several attempts to stop isoflurane anesthesia were
made but seizures returned. After 24 days in treatment (17 days
with isoflurane and HT), the patient was able to be taken off
of anesthesia and recovered rapidly, returning to work within
2 months.
General anesthesia is effective for the largest number of patients
with status epilepticus that are refractory to conventional anticon-
vulsant therapy. However, compared to other general anesthesias,
isoflurane has minimal reported organ toxicities, is rapidly titrat-
able, and moreover, isoflurane lowers the shivering threshold (18),
thereby functioning well as a partner for HT. The application of
isoflurane here was not associated with a severe adverse event.
This is not consistent with previous reports on the adverse effects
of inhalational anesthesia for RSE patients. We believe that the
seizure-causing injury itself may be a significant determinant of
serious adverse events during treatment and this is highly hetero-
geneous for epilepsy patients. It would be useful to determine the
associations between the source of SRSE and the efficacy/risk of
treatments; however, this may require a sample size far exceeding
the expected presentation frequency.
There is a general consensus that isoflurane is associated with
more adverse effects; however, we are not aware of a retrospective
analysis that permits the dissociation of the adverse events asso-
ciated with isoflurane versus the injury itself or other treatments
that always overlap with isoflurane therapy (11). Compared to
established epilepsy treatments (benzodiazepine plus AED), there
is not sufficient evidence that isoflurane is on average an improved
treatment for status epilepticus, however, by its nature, SRSE is a
failure of the established treatments. There is no best known treat-
ment for SRSE largely because it is a rare complication. We propose
that, despite the small number of reported studies, isoflurane and
HT may be a reasonable treatment after standard treatments have
failed (e.g., in SRSE).
Hypothermia is a therapy that deserves further study for
SRSE because of the extensive preclinical experimental evidence
of neuroprotection for epilepsy and almost immediate seizure-
terminating properties in over 80% of patients (19). However,
HT possesses significant potential complications and side effects,
including acid–base imbalance, infection, and coagulopathy. The
level of HT to be effective is also uncertain, and it has been
suggested that only HT between 30 and 34°C has an appro-
priate risk-to-benefit ratio (20). The shifting standards of the
use of therapeutic HT for cardiac arrest have illuminated the
importance of prophylactic antipyresis but are associated with
convincing evidence that the utility of HT may be more limited
than recently believed (21). We need to ask the same question
for status epilepticus; stated crudely – is it safe and does it work
(does it have a favorable risk-to-benefit ratio)? The safety profile
of controlled mild HT is considered manageable and, for RSE,
eliminating seizure activity quickly and in 100% of almost all
patients (even if temporarily) is a truly significant benefit. On
a case by case basis, by the definition of SRSE, if isoflurane or HT
stops seizure activity, then it is superior to the failed treatment (in
that specific case).
CONCLUDING REMARKS
If even short epileptic episodes cause excitotoxicity and brain
damage, then it is imperative that reliable secondary strategies be
adopted for when AEDs fail. While the utility of inhalational anes-
thesia and HT in neurocritical care is debatable, it is clear that these
therapies can be an effective treatment for intractable seizures in
SRSE. At the very least, temporary amelioration of epileptic activ-
ity is expected to improve the long-term outcomes by limiting the
excitotoxic injury.
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